High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria

Gennaro De Pascale, Luca Montini, Mariano Alberto Pennisi, Teresa Spanu, Mario Tumbarello, Massimo Antonelli, Valentina Bernini, Riccardo Maviglia, Giuseppe Bello

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

The high incidence of multidrug-resistant (MDR) bacteria among patients admitted to ICUs has determined an increase of tigecycline (TGC) use for the treatment of severe infections. Many concerns have been raised about the efficacy of this molecule and increased dosages have been proposed. Our purpose is to investigate TGC safety and efficacy at higher than standard doses.
Original languageEnglish
Pages (from-to)R90-R90
Number of pages9
JournalCritical Care
Volume18
DOIs
Publication statusPublished - 2014

Keywords

  • tygecicline

Fingerprint

Dive into the research topics of 'High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria'. Together they form a unique fingerprint.

Cite this